lipogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Some bacteria, such as Shewanella putrefaciens, Geobacter metallireducens and some strains of Burkholderia fungorum, can use uranium for their growth and convert U(VI) to U(IV). Recent research suggests that this pathway includes reduction of the soluble U(VI) via an intermediate U(V) pentavalent state. Other organisms, such as the lichen Trapelia involuta or microorganisms such as the bacterium Citrobacter, can absorb concentrations of uranium that are up to 300 times the level of their environment. Citrobacter species absorb uranyl ions when given glycerol phosphate (or other similar organic phosphates). After one day, one gram of bacteria can encrust themselves with nine grams of uranyl phosphate crystals; this creates the possibility that these organisms could be used in bioremediation to decontaminate uranium-polluted water. The proteobacterium Geobacter has also been shown to bioremediate uranium in ground water. The mycorrhizal fungus Glomus intraradices increases uranium content in the roots of its symbiotic plant. In nature, uranium(VI) forms highly soluble carbonate complexes at alkaline pH. This leads to an increase in mobility and availability of uranium to groundwater and soil from nuclear wastes which leads to health hazards. However, it is difficult to precipitate uranium as phosphate in the presence of excess carbonate at alkaline pH. A Sphingomonas sp. strain BSAR-1 has been found to express a high activity alkaline phosphatase (PhoK) that has been applied for bioprecipitation of uranium as uranyl phosphate species from alkaline solutions.
=== Unconventional molecular biology === The objective of the "unnatural molecular biology" strategy is to create new varieties of life that are based on a different kind of molecular biology, such as new types of nucleic acids or a new genetic code. The creation of new types of nucleotides that can be built into unique nucleic acids could be accomplished by changing certain DNA or RNA constituents, such as the bases or the backbone sugars. The normal genetic code is being altered by inserting quadruplet codons or changing some codons to encode new amino acids, which would subsequently permit the use of non-natural amino acids with unique features in protein production. It is a scientific and technological problem to adjust the enzymatic machinery of the cell for both approaches. A new sort of life would be formed by organisms with a genome built on synthetic nucleic acids or on a totally new coding system for synthetic amino acids. This new style of life would have some benefits but also some new dangers. On release into the environment, there would be no horizontal gene transfer or outcrossing of genes with natural species. Furthermore, these kinds of synthetic organisms might be created to require non-natural materials for protein or nucleic acid synthesis, rendering them unable to thrive in the wild if they accidentally escaped.
== Women's rights == The Ba'athist regime in Syria discriminated against women through administrative measures that silenced their voices and through deploying political violence disproportionately against women. Sexual violence has long been a strategy of the regime to enforce the compliance of the populace. During the Syrian civil war, mass-rapes have been weaponized as a large-scale war-tactic by the Assad regime and the Ba'athist militant forces across Syria. Sexual violence against women on a political and sectarian basis has been described as a fundamental pillar of the regime's military strategy. Anti-Sunni Shabiha and other pro-Assad death squads carry out this policy on a sectarian basis, against Sunni women and girls. Many women suspected of pro-opposition sympathies are rounded up by Ba'athist paramilitaries and sexually assaulted in government detention centres and military prisons. Rural and poor women get disproportionately raped, assaulted, beaten and tortured in military prisons. Several women get abducted by dreaded Mukhabarat and raped in the offices of the secret police. According to many survivors, they can't return to their society without justice against the perpetrators.
=== Anti-aging and rejuvenation treatment === Solar UV radiation accelerates the skin ageing rate and contributes to abnormal cutaneous status by increasing matrix-metalloproteinase (MMP) expression in photo-damaged skin. MMPs consist of various proteinases that degrade collagen fibrils and other components of the cutaneous extracellular matrix. The commonly used therapies for skin ageing involve the use of retinoic acid, laser resurfacing, peels (trichloroacetic acid and CO2), injectable skin rejuvenation, and dermal fillers. In comparison, LEDT is a more non-ablative cutaneous rejuvenation approach with less safety concern and higher effectiveness. LECT with yellow LED (at a wavelength of 590 nm) contributes to the skin rejuvenation effects on nearly a thousand clinical samples. Researchers conclude that the use of red-light LEDT is an efficient collagen enhancement strategy. LEDT's combination therapy of different light wavelengths also shows greater efficacy. For instance, blue-light LEDT coupled with photosensitizers reveals better elasticity, less pigmentation, and more complexion of the skin.
Sources: en.wikipedia.org
Executive Order 14148, titled "Initial Rescissions of Harmful Executive Orders and Actions", is an executive order signed by United States president Donald Trump on January 20, 2025, during the first day of his second presidential term. The order directed the rescindment of several executive orders enacted during the Biden administration. The main focus of the order was to rescind diversity, equity, and inclusion (DEI) policies in the US Government, specific climate and environmental regulations, and certain border policies.
=== Reorganization after 1949 === Following the Communist party took over Chengdu in 1949, the institution underwent several reorganizations and name changes. In 1951, West China Union University was renamed West China University. In 1953, following the nationwide restructuring of higher education, it became the Department of Stomatology and affiliated stomatological hospital of Sichuan Medical College. China's first dedicated oral and maxillofacial surgery ward was also established there in 1953. A Research Institute of Stomatology was established in 1958. In 1966, a purpose-built stomatological hospital building was completed, while postgraduate education expanded in the following decades. The institution became an authorized master's-degree training site in stomatology in 1978 and a doctoral-degree training site in 1981. In 1985, Sichuan Medical College was renamed the West China University of Medical Sciences, and the dental institution became its College of Stomatology and affiliated stomatological hospital. The hospital was recognized as a Grade-III, Class-A stomatological specialist hospital in 1997.
== Works == Gish, Duane T. 15 Scopus Publishers. Gish, Duane T. (1972). Speculations and Experiments on the Origins of Life. New Leaf Pr. ISBN 0-89051-010-5. Gish, Duane T. (1972). Evidence against evolution. Wheaton, Ill: Tyndale House Publishers. ISBN 0-8423-0790-7. Gish, Duane T. (1986) [1972]. Evolution, the fossils say no!. San Diego, Calif: Institute for Creation Research Publishing. ISBN 0-89051-057-1. Gish, Duane T. (1973). Have You Been... Brainwashed?. Seattle, Washington: Life Messengers. p. 32. OCLC 10930514. Hillestad, George M.; Morris, Henry; Gish, Duane T. (1974). Creation: acts, facts, impacts. San Diego, Calif: ICR Pub. Co. ISBN 0-89051-020-2. Gish, Duane T. (1977). Dinosaurs: Those Terrible Lizards. Green forest, Arkansas: Master Books. ISBN 0-89051-039-3. Rohrer, Donald H.; Gish, Duane T. (1978). Up with creation!: ICR acts/facts/impacts, 1976-1977. San Diego, California: Creation-Life Publishers. ISBN 0-89051-048-2. Gish, Duane T.; Wilson, Clifford (1981). Manipulating life, where does it stop?: Genetic engineering. Green Forest, Arkansas: Master Books. ISBN 0-89051-071-7. Gish, Duane T. (1985). Evolution: the challenge of the fossil record. San Diego, Calif: Creation-Life Publishers. ISBN 0-89051-112-8. Gish, Duane T. (1988). Creationist Research 1964-1988. Creation Research Society. ISBN 0-940384-06-X. Bonnie Snellenberger; Gish, Duane T.; D Dish; Earl Snellenberger (1990). The Amazing Story of Creation: From Science and the Bible. Green Forest, Arkansas: Master Books. ISBN 0-89051-120-9.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.